Literature DB >> 27450367

Leigh-Like Syndrome Due to Homoplasmic m.8993T>G Variant with Hypocitrullinemia and Unusual Biochemical Features Suggestive of Multiple Carboxylase Deficiency (MCD).

Shanti Balasubramaniam1,2,3, B Lewis4, D M Mock5, H M Said6, M Tarailo-Graovac7, A Mattman8, C D van Karnebeek9, D R Thorburn10,11, R J Rodenburg12, J Christodoulou10,11.   

Abstract

Leigh syndrome (LS), or subacute necrotizing encephalomyelopathy, is a genetically heterogeneous, relentlessly progressive, devastating neurodegenerative disorder that usually presents in infancy or early childhood. A diagnosis of Leigh-like syndrome may be considered in individuals who do not fulfil the stringent diagnostic criteria but have features resembling Leigh syndrome.We describe a unique presentation of Leigh-like syndrome in a 3-year-old boy with elevated 3-hydroxyisovalerylcarnitine (C5-OH) on newborn screening (NBS). Subsequent persistent plasma elevations of C5-OH and propionylcarnitine (C3) as well as fluctuating urinary markers were suggestive of multiple carboxylase deficiency (MCD). Normal enzymology and mutational analysis of genes encoding holocarboxylase synthetase (HLCS) and biotinidase (BTD) excluded MCD. Biotin uptake studies were normal excluding biotin transporter deficiency. His clinical features at 13 months of age comprised psychomotor delay, central hypotonia, myopathy, failure to thrive, hypocitrullinemia, recurrent episodes of decompensation with metabolic keto-lactic acidosis and an episode of hyperammonemia. Biotin treatment from 13 months of age was associated with increased patient activity, alertness, and attainment of new developmental milestones, despite lack of biochemical improvements. Whole exome sequencing (WES) analysis failed to identify any other variants which could likely contribute to the observed phenotype, apart from the homoplasmic (100%) m.8993T>G variant initially detected by mitochondrial DNA (mtDNA) sequencing.Hypocitrullinemia has been reported in patients with the m.8993T>G variant and other mitochondrial disorders. However, persistent plasma elevations of C3 and C5-OH have previously only been reported in one other patient with this homoplasmic mutation. We suggest considering the m.8993T>G variant early in the diagnostic evaluation of MCD-like biochemical disturbances, particularly when associated with hypocitrullinemia on NBS and subsequent confirmatory tests. An oral biotin trial is also warranted.

Entities:  

Keywords:  Acylcarnitines; Citrulline; Leigh syndrome; Newborn screening (NBS); mtDNA mutation

Year:  2016        PMID: 27450367      PMCID: PMC5413447          DOI: 10.1007/8904_2016_559

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  39 in total

1.  Genetic counseling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993.

Authors:  S L White; V R Collins; R Wolfe; M A Cleary; S Shanske; S DiMauro; H H Dahl; D R Thorburn
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Determinations of biotin in biological fluids.

Authors:  D M Mock
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

3.  Skewed segregation of the mtDNA nt 8993 (T-->G) mutation in human oocytes.

Authors:  R B Blok; D A Gook; D R Thorburn; H H Dahl
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Pearson syndrome: altered tricarboxylic acid and urea-cycle metabolites, adrenal insufficiency and corneal opacities.

Authors:  A Ribes; E Riudor; R Valcárel; A Salvá; F Castelló; S Murillo; C Dominguez; A Rötig; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

5.  The effects of deimination of myelin basic protein on structures formed by its interaction with phosphoinositide-containing lipid monolayers.

Authors:  N Ishiyama; I R Bates; C M Hill; D D Wood; P Matharu; N J Viner; M A Moscarello; G Harauz
Journal:  J Struct Biol       Date:  2001-10       Impact factor: 2.867

6.  Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations.

Authors:  Elsebet Ostergaard; Flemming J Hansen; Nicolina Sorensen; Morten Duno; John Vissing; Pernille L Larsen; Oddmar Faeroe; Sigurdur Thorgrimsson; Flemming Wibrand; Ernst Christensen; Marianne Schwartz
Journal:  Brain       Date:  2007-02-07       Impact factor: 13.501

7.  Clinical, metabolic, and genetic aspects of cytochrome C oxidase deficiency in Saguenay-Lac-Saint-Jean.

Authors:  C Morin; G Mitchell; J Larochelle; M Lambert; H Ogier; B H Robinson; M De Braekeleer
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

8.  Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage.

Authors:  Ludy C H W Lutgens; Nicolaas E P Deutz; John Gueulette; Jack P M Cleutjens; Martijn P F Berger; Bradly G Wouters; Maarten F von Meyenfeldt; Philippe Lambin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-15       Impact factor: 7.038

9.  Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia.

Authors:  Kondala R Atkuri; Tina M Cowan; Tony Kwan; Angelina Ng; Leonard A Herzenberg; Leonore A Herzenberg; Gregory M Enns
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

10.  m.8993T>G-Associated Leigh Syndrome with Hypocitrullinemia on Newborn Screening.

Authors:  Mari Mori; John R Mytinger; Lisa C Martin; Dennis Bartholomew; Scott Hickey
Journal:  JIMD Rep       Date:  2014-09-21
View more
  7 in total

1.  8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease.

Authors:  Rebecca D Ganetzky; Marni J Falk
Journal:  Mol Genet Metab       Date:  2018-02-02       Impact factor: 4.797

Review 2.  Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases.

Authors:  Kei Murayama; Masaru Shimura; Zhimei Liu; Yasushi Okazaki; Akira Ohtake
Journal:  J Hum Genet       Date:  2018-11-21       Impact factor: 3.172

3.  The role of the clinician in the multi-omics era: are you ready?

Authors:  Clara D M van Karnebeek; Saskia B Wortmann; Maja Tarailo-Graovac; Mirjam Langeveld; Carlos R Ferreira; Jiddeke M van de Kamp; Carla E Hollak; Wyeth W Wasserman; Hans R Waterham; Ron A Wevers; Tobias B Haack; Ronald J A Wanders; Kym M Boycott
Journal:  J Inherit Metab Dis       Date:  2018-01-23       Impact factor: 4.982

4.  Vaccination triggering onset of m.8993T > G associated Leigh syndrome.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Mol Genet Metab Rep       Date:  2018-04-25

5.  [Genetic analysis of newborns with abnormal metabolism of 3-hydroxyisovalerylcarnitine].

Authors:  Dingwen Wu; Bin Lu; Jianbin Yang; Rulai Yang; Xinwen Huang; Fan Tong; Jing Zheng; Zhengyan Zhao
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-25

6.  Prospective diagnosis of MT-ATP6-related mitochondrial disease by newborn screening.

Authors:  Ryan H Peretz; Nicholas Ah Mew; Hilary J Vernon; Rebecca D Ganetzky
Journal:  Mol Genet Metab       Date:  2021-06-24       Impact factor: 4.204

7.  Targeted Therapies for Leigh Syndrome: Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  May Yung Tiet; Zhiyuan Lin; Fei Gao; Matthew James Jennings; Rita Horvath
Journal:  J Neuromuscul Dis       Date:  2021
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.